COUNT D. GIBSON JR., M.D.; HARRY NUSHAN, M.D.; DAN N. ANDERSON, M.D.
This content is PDF only. Please click on the PDF icon to access.
Twenty years ago no specific agent (with the exception of antiserum) was available for the treatment of pneumococcal pneumonia. Today the physician is confronted with a variety of drugs which can favorably modify this disease. The sulfonamides,1 penicillin,2 bacitracin,3 chlortetracycline,2 oxytetracycline4 and chloramphenicol2 are all of proved clinical value. Of these, none has been proved more efficacious or in general less toxic than penicillin.
In 1952 a new antibiotic, erythromycin, was made available for clinical study.5 In vitro studies indicated that the pneumococcus was inhibited by 0.1 microgram/ml. of the drug. Several case reports suggested that good results were obtained
GIBSON CD, NUSHAN H, ANDERSON DN. THE TREATMENT OF BACTERIAL PNEUMONIA WITH ERYTHROMYCIN: A CONTROLLED CLINICAL STUDY*. Ann Intern Med. 1954;41:112–117. doi: https://doi.org/10.7326/0003-4819-41-1-112
Download citation file:
Published: Ann Intern Med. 1954;41(1):112-117.
Infectious Disease, Pneumonia, Pulmonary/Critical Care.
Results provided by:
Copyright © 2019 American College of Physicians. All Rights Reserved.
Print ISSN: 0003-4819 | Online ISSN: 1539-3704
Conditions of Use